This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jorgensen, J. H.
Right arrow Articles by Whitney, C. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jorgensen, J. H.
Right arrow Articles by Whitney, C. G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2004, p. 605-607, Vol. 48, No. 2
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.2.605-607.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Activities of Cethromycin and Telithromycin against Recent North American Isolates of Streptococcus pneumoniae

James H. Jorgensen,1* Sharon A. Crawford,1 M. Leticia McElmeel,1 and Cynthia G. Whitney2

Department of Pathology, University of Texas Health Science Center, San Antonio, Texas,1 Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia2

Received 16 May 2003/ Returned for modification 1 September 2003/ Accepted 19 October 2003


arrow
ABSTRACT
 
The in vitro activities of two investigational ketolides, cethromycin (formerly ABT-773) and telithromycin, were determined for a selected group of 312 Streptococcus pneumoniae isolates from a national surveillance program. The MIC of cethromycin at which 50% of the isolates were inhibited was 0.008 µg/ml, and the MIC at which 90% of the isolates were inhibited was 0.06 µg/ml; the corresponding values for telithromycin were <=0.015 and 0.25 µg/ml, respectively. For six quinupristin-dalfopristin-resistant strains, the cethromycin MICs were 0.25 to 16 µg/ml and the telithromycin MICs were 1 to 4 µg/ml. However, there was only 0.3% resistance to telithromycin.


arrow
INTRODUCTION
 
The prevalence of antimicrobial agent resistance among both invasive and respiratory isolates of Streptococcus pneumoniae has increased substantially throughout the world in the past decade (2, 6, 8, 25). In addition to resistance to penicillin, older-generation cephalosporins, chloramphenicol, tetracycline, and trimethoprim-sulfamethoxazole, resistance to extended-spectrum cephalosporins and fluoroquinolones has been noted (3, 4, 6, 10, 25). Two types of resistance to macrolides have been demonstrated, one that affects both macrolides and lincosamides by virtue of structural modification of the ribosomal target site by methylation [MLSB-type resistance mediated primarily by erm(B)] and one that affects only the macrolides [M phenotype encoded by mef(A)] due to an efflux pump (11, 23, 24). Both mechanisms of macrolide resistance have been associated with therapeutic failures of pneumococcal infections (12, 13). Ketolides represent a new structural modification of the macrolide structure (a ketone group replacing the cladinose moiety at the 3 position of the erythronolide A ring), with the resulting addition of a second ribosomal binding site at domain V as well as at domain II of the 23S RNA subunit (9). This structure results in good activity of ketolides against many macrolide- and lincosamide-resistant gram-positive bacteria (9, 14, 18, 20).

The Centers for Disease Control and Prevention has performed intensive surveillance in North America since 1994 for resistance among invasive pneumococcal isolates through its Active Bacterial Core Surveillance of the Emerging Infections Program (11, 25). In the years 1994 to 1996, nine sites located in various areas of the United States and Canada collected pneumococcal clinical isolates and patient data; from 1997 to 2000, seven of the sites continued with the surveillance program. A group of 312 isolates was selected for assessment of the in vitro activities of two investigational ketolide antibiotics intended for therapy of pneumococcal respiratory infections. These isolates included 162 isolates that reflected resistance mechanisms affecting most antimicrobial agent classes in current clinical use (e.g., 70 resistant to penicillin, 32 to cefotaxime, 93 to erythromycin, 47 to clindamycin, 6 to quinupristin-dalfopristin, 18 to levofloxacin, 56 to tetracycline, and 111 to trimethoprim-sulfamethoxazole), and an additional 150 susceptible isolates that were randomly selected from among the Active Bacterial Core Surveillance isolate collection of 1994 to 1998; the selection was weighted to represent equally all of the surveillance sites.

The ketolides examined in this study included cethromycin (formerly ABT-773; kindly provided by Abbott Laboratories, North Chicago, Ill.) and telithromycin (formerly HMR 3647; kindly provided by Aventis Pharmaceuticals, Romainville, France). Reagent powders of penicillin, cefotaxime, erythromycin, clindamycin, and quinupristin-dalfopristin were provided by their manufacturers or obtained from Sigma Chemical Company. The MICs of the ketolides and the comparative agents were determined by using the broth microdilution susceptibility test method recommended by the NCCLS (16). This method included use of cation-adjusted Mueller-Hinton broth supplemented with 3% lysed horse blood as the test medium, an inoculum density of 5 x 105 CFU/ml, and incubation at 35°C in ambient air for 20 to 24 h prior to visual determination of the MICs. S. pneumoniae strain ATCC 49619 was tested for quality control purposes.

PCR tests were performed for erm(B) and mef(A) genes on 11 isolates selected because of elevated ketolide MICs and on 8 representative ketolide-susceptible isolates. Oligonucleotide primers were used to amplify a 1.7-kbp segment containing the mef(A) or mef(E) gene (23) or a 639-bp segment containing the erm(B) gene fragment (22). Positive controls for each primer pair and a negative control (S. pneumoniae strain ATCC 49619) were included. In addition, an internal control consisting of primers for RR142, a 400-bp conserved region of S. pneumoniae (24), was employed to demonstrate adequate DNA for amplification and the absence of inhibitors.

Both cethromycin and telithromycin MICs were generally very low for this selected group of pneumococcal strains (Table 1) and especially for the erythromycin-susceptible strains examined (MICs of both ketolides for these strains were <=0.03 µg/ml) (Table 2). However, erythromycin-resistant strains were associated with slightly elevated cethromycin and telithromycin MICs, as depicted in Table 2. Indeed, the modal MICs of the two ketolides were 3 to 5 dilutions higher for the M phenotype isolates than for the fully susceptible or the MLSB phenotype strains. Perhaps the minimal effect of MLSB resistance on cethromycin and telithromycin MICs is due to the second ribosomal binding site of the ketolides (8). The activities of both ketolides were most influenced by resistance to the streptogramin antibiotic, quinupristin-dalfopristin (Table 2). For six quinupristin-dalfopristin-resistant strains, cethromycin MICs were 0.25 to 16 µg/ml (only one strain was associated with a cethromycin MIC of 16 µg/ml; all others were <=1 µg/ml), and telithromycin MICs were 1 to 4 µg/ml. This result translated to only 0.3% (1 of 312) resistance to telithromycin based upon the recently decided NCCLS breakpoints for pneumococci (susceptible, MIC of <=1 µg/ml; intermediate, MIC of 2 µg/ml; and resistant, MIC of >=4 µg/ml) (T. Dooley, personal communication). With the exception of the six streptogramin-resistant strains, our findings are consistent with earlier reports (1, 5, 14, 18, 19, 20, 21) that indicated that both cethromycin and telithromycin were very active against pneumococcal strains of the efflux or MLSB phenotypes, although the MICs reported in those studies did not exceed 2 µg/ml, and telithromycin MICs usually did not exceed 1 µg/ml (1, 5, 20). PCR analysis of the six streptogramin-resistant strains with elevated cethromycin MICs did not reveal the presence of either erm(B) or mef(A) sequences. Thus, the mechanism responsible for the elevated ketolide MICs among this subset of our strains was neither of the most common macrolide resistance mechanisms. It is possible that these strains contained a different erm or mef gene or one or more mutations in the genes that encode the structure of the 23S ribosomal subunits such as the L22 or L4 proteins (7, 15, 21).


View this table:
[in this window]
[in a new window]
  		TABLE 1. MICs of cethromycin, telithromycin, and comparative agents against a collection of 312 North American S. pneumoniae invasive clinical isolates


View this table:
[in this window]
[in a new window]
  		TABLE 2. Cethromycin and telithromycin MICs displayed according to macrolide, lincosamide, and streptogramin susceptibility

These in vitro data suggest the potential utility of cethromycin or telithromycin in the therapy of drug-resistant pneumococcal infections, depending upon the pharmacokinetic and pharmacodynamic properties as well as the safety profiles of the drugs in humans.


arrow
ACKNOWLEDGMENTS
 
This study was supported in part by grants from Abbott Laboratories and by Aventis Pharmaceuticals.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Department of Pathology, University of Texas Health Science Center, 7703 Floyd Curl Dr., San Antonio, TX 78229-3900. Phone: (210) 567-4088. Fax: (210) 567-2367. E-mail: jorgensen{at}uthscsa.edu. Back


arrow
REFERENCES
 
    1
  1. Barry, A. L., P. C. Fuchs, and S. D. Brown. 1998. Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin). Antimicrob. Agents Chemother. 42:945-946.[Abstract/Free Full Text]
    2. 2
  2. Butler, J. C., J. Hofmann, M. S. Cetron, J. A. Elliott, R. R. Facklam, and R. F. Breiman. 1996. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's pneumococcal surveillance system. J. Infect. Dis. 174:986-993.[Medline]
    3. 3
  3. Chen, D. K., A. McGeer, J. C. de Azavedo, and D. E. Low. 1999. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 341:233-239.[Abstract/Free Full Text]
    4. 4
  4. Davidson, R., R. Cavalcanti, J. L. Brunton, D. J. Bast, J. C. S. de Azavedo, P. Kibsey, C. Fleming, and D. E. Low. 2002. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N. Engl. J. Med. 346:747-750.[Free Full Text]
    5. 5
  5. Davies, T. A., L. M. Kelly, M. R. Jacobs, and P. C. Appelbaum. 2000. Antipneumococcal activity of telithromycin by agar dilution, microdilution, E test, and disk diffusion methodologies. J. Clin. Microbiol. 38:1444-1448.[Abstract/Free Full Text]
    6. 6
  6. Doern, G. V., A. B. Brueggemann, H. Huynh, E. Wingert, and P. Rhomberg. 1999. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-98. Emerg. Infect. Dis. 5:757-765.[Medline]
    7. 7
  7. Farrel, D. J., S. Douthwaite, I. Morrissey, S. Bakker, J. Poehlsgaard, L. Jakobsen, and D. Felmingham. 2003. Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study. Antimicrob. Agents Chemother. 47:1777-1783.
    8. 8
  8. Feikin, D. R., A. Schuchat, M. Kolczak, N. L. Barrett, L. H. Harrison, L. Lefkowitz, A. McGeer, M. M. Farley, D. J. Vugia, C. Lexau, K. R. Stefonek, J. E. Patterson, and J. H. Jorgensen. 2000. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am. J. Publ. Health 90:223-229.[Abstract/Free Full Text]
    9. 9
  9. Hansen, L., H. Mauvais, and S. Douthwaite. 1999. The macrolide-ketolide antibiotic binding site is formed by structures in domain II and V of 23S ribosomal RNA. Mol. Microbiol. 31:623-631.[CrossRef][Medline]
    10. 10
  10. Ho, P. L., T. L. Que, D. N. Tsang, T. K. Ng, K. H. Chow, and W. H. Seto. 1999. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob. Agents Chemother. 43:1310-1313.[Abstract/Free Full Text]
    11. 11
  11. Hyde, T. B., K. Gay, D. S. Stephens, D. J. Vugia, M. Pass, S. Johnson, N. L. Barrett, W. Schaffner, P. R. Cieslak, P. S. Maupin, E. R. Zell, J. H. Jorgensen, R. R. Facklam, and C. G. Whitney. 2001. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 286:1857-1862.[Abstract/Free Full Text]
    12. 12
  12. Kelley, M. A., D. M, Weber, P. Gilligan, and M. S. Cohen. 2000. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin. Infect. Dis. 31:1008-1011.[CrossRef][Medline]
    13. 13
  13. Lonks, J. R., J. Garau, L. Gomez, M. Xercavins, A. Ochoa de Exhaguen, I. F. Gareen, P. T. Reiss, and A. A. Madeiros. 2002. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin. Infect. Dis. 35:556-564.[CrossRef][Medline]
    14. 14
  14. Mason, E. O., Jr., L. B. Lamberth, E. R. Wald, J. S. Bradley, W. J. Barson, and S. L. Kaplan. 2003. In vitro activities of cethromycin (ABT-773), a new ketolide, against Streptococcus pneumoniae strains that are not susceptible to penicillin or macrolides. Antimicrob. Agents Chemother. 47:166-169.[Abstract/Free Full Text]
    15. 15
  15. Musher, D. M., M. E. Dowell, V. D. Shortridge, R. K. Flamm, J. H. Jorgensen, P. Le Magueres, and K. L. Krause. 2002. Emergence of macrolide resistance during treatment of pneumococcal pneumonia with azithromycin. N. Engl. J. Med. 346:630-631.[Free Full Text]
    16. 16
  16. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
    17. 17
  17. National Committee for Clinical Laboratory Standards. 2003. Performance standards for antimicrobial susceptibility testing. Supplement M100-S13. National Committee for Clinical Laboratory Standards, Wayne, Pa.
    18. 18
  18. Nilius, A. M., M. H. Bui, L. Almer, D. Hensey-Rudloff, J. Beyer, Z. Ma, Y. S. Or, and R. K. Flamm. 2001. Comparative in vitro activity of ABT-773, a novel antibacterial ketolide. Antimicrob. Agents Chemother. 45:2163-2168.[Abstract/Free Full Text]
    19. 19
  19. Nilius, A. M., D. M. Hensey-Rudloff, M. A. Reimann, and R. K. Flamm. 2002. Comparison of selection for mutants with reduced susceptibility to ABT-773, erythromycin and rifampicin in respiratory tract pathogens. J. Antimicrob. Chemother. 49:831-836.[Abstract/Free Full Text]
    20. 20
  20. Pankuch, G. A., M. A. Visalli, M. R. Jacobs, and P. C. Appelbaum. 1998. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob. Agents Chemother. 42:624-630.[Abstract/Free Full Text]
    21. 21
  21. Shortridge, V. D., P. Zhong, Z. Cao, J. M. Beyer, L. S. Almer, N. Ramer, S. Z. Doktor, and R. K. Flamm. 2002. Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci. Antimicrob. Agents Chemother. 46:783-786.[Abstract/Free Full Text]
    22. 22
  22. Sutcliffe, J., T. Grebe, A. Tait-Kamradt, and L. Wondrack. 1996. Detection of erythromycin-resistant determinants by PCR. Antimicrob. Agents Chemother. 40:2562-2566.[Abstract]
    23. 23
  23. Tait-Kamradt, A., J. Clancy, M. Cronan, F. Dib-Haji, L. Wondrack, W. Yuan, and J. Sutcliffe. 1997. mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:2251-2255.[Abstract]
    24. 24
  24. Waites, K., C. Johnson, B. Gray, K. Edwards, M. Crain, W. Benjamin, Jr. 2000. Use of clindamycin disks to predict macrolide resistance mediated by ermB and mefE in Streptococcus pneumoniae. J. Clin. Microbiol. 38:1731-1734.[Abstract/Free Full Text]
    25. 25
  25. Whitney, C. G., M. M. Farley, J. Hadler, L. H. Harrison, C. Lexau, A. Reingold, L. Lefkowitz, P. R. Cieslak, M. Cetron, E. R. Zell, J. H. Jorgensen, and A. Schuchat. 2001. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N. Engl. J. Med. 343:1917-1924.

Antimicrobial Agents and Chemotherapy, February 2004, p. 605-607, Vol. 48, No. 2
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.2.605-607.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Azoulay-Dupuis, E., Mohler, J., Bedos, J. P., Barau, C., Fantin, B. (2006). Efficacy of Cethromycin, a New Ketolide, against Streptococcus pneumoniae Susceptible or Resistant to Erythromycin in a Murine Pneumonia Model.. Antimicrob. Agents Chemother. 50: 3033-3038 [Abstract] [Full Text]  
  • Zhanel, G. G., Johanson, C., Laing, N., Hisanaga, T., Wierzbowski, A., Hoban, D. J. (2005). Pharmacodynamic Activity of Telithromycin at Simulated Clinically Achievable Free-Drug Concentrations in Serum and Epithelial Lining Fluid against Efflux (mefE)-Producing Macrolide- Resistant Streptococcus pneumoniae for Which Telithromycin MICs Vary. Antimicrob. Agents Chemother. 49: 1943-1948 [Abstract] [Full Text]  
  • Kasbekar, N., Acharya, P. S. (2005). Telithromycin: The first ketolide for the treatment of respiratory infections. Am J Health Syst Pharm 62: 905-916 [Abstract] [Full Text]  
  • Daly, M. M., Doktor, S., Flamm, R., Shortridge, D. (2004). Characterization and Prevalence of MefA, MefE, and the Associated msr(D) Gene in Streptococcus pneumoniae Clinical Isolates. J. Clin. Microbiol. 42: 3570-3574 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jorgensen, J. H.
Right arrow Articles by Whitney, C. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jorgensen, J. H.
Right arrow Articles by Whitney, C. G.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»